quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·56d
PRRelease
Atea Pharmaceuticals Inc. logo

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

AVIR· Atea Pharmaceuticals Inc.
Health Care
Original source

Companies

  • AVIR
    Atea Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Aug 13UpdateMorgan Stanley$6.88
  • Aug 10UpdateJP Morgan-
  • Mar 2UpdateJP Morgan$8.00
  • Mar 1UpdateSVB Leerink$9.00
  • Feb 16UpdateSVB Leerink$10.00
  • Jan 6UpdateMorgan Stanley$7.00

Related

  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.
  • PR30d
    ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
  • INSIDER41d
    Officer Corcoran Andrea exercised 60,000 shares at a strike of $1.24, increasing direct ownership by 8% to 823,576 units (SEC Form 4)
  • SEC49d
    SEC Form 10-K filed by Atea Pharmaceuticals Inc.
  • SEC49d
    Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
  • PR49d
    Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • PR58d
    Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
  • SEC73d
    SEC Form SCHEDULE 13G filed by Atea Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022